Polymorphisms Associated with Increased Cardiovascular Risk in the General Population do not Predict Acute Events in

Clinical Laboratory
|May 25, 2016
PubMed

Insights

Genetic factors common in the general population do not predict cardiovascular events in hemodialysis patients. This study found no association between these polymorphisms and cardiac or vascular events in this high-risk group.

Area of Science:

  • Nephrology
  • Cardiology
  • Genetics

Background:

  • Cardiovascular diseases (CVD) are a primary cause of death in hemodialysis patients (HP).
  • Understanding genetic predispositions to CVD in HP is crucial for developing new prevention strategies.
  • This study investigates known genetic risk factors for CVD in the general population within the HP cohort.

Purpose of the Study:

  • To analyze specific genetic polymorphisms in hemodialysis patients.
  • To determine if these polymorphisms, associated with CVD risk in the general population, are also prevalent in HP.
  • To assess the predictive value of these genetic factors for cardiovascular events in HP.

Main Methods:

  • Genotyping of 102 hemodialysis patients for 15 cardiovascular risk-associated polymorphisms.
  • Comparison of polymorphism prevalence in HP versus the general Caucasian population.
  • Correlation analysis between identified polymorphisms and recorded cardiovascular events over an 18-month follow-up.

Main Results:

  • Prevalence of FV H1299R, PAI-1 (4G/5G), and Factor XIII V34L polymorphisms was significantly higher in HP compared to the general population.
  • No significant differences were found for other analyzed polymorphisms.
  • None of the investigated genetic polymorphisms were associated with cardiovascular events in HP during the follow-up period.

Conclusions:

  • Traditional genetic risk factors for cardiovascular disease do not appear to predict acute cardiac, peripheral vascular, or cerebral vascular events in hemodialysis patients.
  • These findings suggest that other factors may be more influential in determining cardiovascular outcomes in this patient population.
  • Further research is needed to identify novel predictive markers and prevention strategies for CVD in HP.
Abstract

Related Concept Videos

Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
1.6K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
906
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
102
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
456
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
1.9K